GondolaBio
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3160 Porter Dr 250, Palo Alto, Californi...Website
www.gondolabio.comRevenue
<$5 MillionIndustry
About GondolaBio
GondolaBio Org Chart
Senior Director, Bd & Operations
Senior Director, Bd & Operations
Director, Bd & Operations
Director, Bd & Operations
Is GondolaBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when GondolaBio launches new products
Funding: Get notified immidiatlly once GondolaBio has new funding data
Check out if GondolaBio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at GondolaBio
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on GondolaBio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if GondolaBio had a recent Job posting/layoffs
GondolaBio, which may be a good buyer, showed buying intent in Masked Content Topic
Check if GondolaBio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
GondolaBio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
GondolaBio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about GondolaBio.
GondolaBio Tech Stack
Most Recent Scoops
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GondolaBio
GondolaBio, founded in 2024 as a spinout of BridgeBio Pharma, aims to develop next-generation therapeutics for genetic diseases with substantial backing of $300 million in private financing. The company focuses on leveraging advanced biological research to create innovative medicines addressing significant unmet needs across various therapeutic are... Read More